Opthea Limited
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 650 Chapel Street South Yarra VIC Australia 3141
- IPO Date
- Oct 16, 2020
- CIK
- 0001815620
- Website
- opthea.com
- Similar Companies
- Business
- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical-stage biopharmaceutical company, develops novel biologic therapies targeting vascular endothelial growth factors (VEGF) C, D and receptor-3 to treat vision-threatening retinal diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME); its lead product candidate, sozinibercept (OPT-302), is a first-in-class VEGF-C/D trap inhibitor designed for combination use with standard-of-care anti-VEGF-A therapies such as aflibercept or ranibizumab to enhance visual acuity outcomes. The company, founded in 1984 and headquartered in South Yarra, Australia, operates principally through its United States and Australia segments, serving the biotechnology and ophthalmology sectors with a focus on patients unresponsive to existing VEGF-A monotherapy. Recently, Opthea reached a settlement with DFA Investors in 2025 involving a USD20 million cash payment and issuance of 136.7 million shares following the failure of its Phase 3 COAST and ShORe trials for sozinibercept in wet AMD; concurrently announced the departure of CEO Dr. Fred Guerard, CFO Tom Reilly and Director Sujal Shah, with Chairman Dr. Jeremy Levin assuming CEO duties amid an over 80% workforce reduction and a strategic review supported by approximately USD20 million in remaining cash; earlier milestones included completion of commercial-scale drug product process performance qualification in February 2025 and a A$227 million capital raise in 2024, formerly known as Circadian Technologies Limited prior to its 2015 name change.
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Here’s What Happened
Opthea Provides Corporate Update
Opthea Announces Decision to Discontinue Wet AMD Trials
Opthea Announces COAST Phase 3 Trial Topline Results
Opthea Announces Phase 2b Wet AMD Publication
Opthea to Present at Oppenheimer Healthcare Conference
Opthea Wet AMD Data Featured at Macula Society Meeting
Opthea to Host Investor Days in New York and Australia
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Opthea's Wet AMD Program to be Featured at FLORetina 2024
Opthea Appoints Kathy Connell to Board of Directors
Opthea Wet AMD Program to be Presented at Innovate Retina
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
Opthea Announces Executive Leadership Changes and Senior Hires
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
Opthea Reports Full-Year Financial Results and Business Updates